Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Suspended × ON 01910 × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 2 talimogene laherparepvec 1 sargramostim 1 romiplostim 1 imisopasem manganese 1 gusacitinib 1 dabrafenib 1 cobimetinib 1 Propranolol 1 Paclitaxel 1 ON 01910 1 Microscopy, Confocal 1 Magnetic Resonance Spectroscopy 1 Drug Therapy 1 Curettage 1 CA-4948 1 Biopsy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05764395 2024-10-10

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Vanderbilt-Ingram Cancer Center

Phase 2 Suspended

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡